

MESKACEL

PHARMACEUTICAL EXCIPIENTS

Meska Joinway Pharmaceutical Co.,
Ltd.

Headquarter:

No. 366, Zijing road, Huzhou city,
Zhejiang 313000 China

Production:

Linghu town, Huzhou City,
Zhejiang, 313000, China

Email:

sales@joinwaypharm.cn

Website:

www.meskajoinway.com



COMPANY PROFILE

Meska Joinway Pharmaceutical Co., Ltd. has been a trusted manufacturer of pharmaceutical excipients since its establishment in 2003, operating in full compliance with Good Manufacturing Practice (GMP) standards. We specialize in providing a comprehensive portfolio of cellulose ethers and high-performance excipients designed to optimize formulation development, improve solubility, and enhance the delivery of active pharmaceutical ingredients.

Since 2003, Meska Joinway has built a strong global presence, serving customers across multiple countries and fostering long-term, reliable partnerships in the pharmaceutical industry.



QUALITY ASSURANCE

In line with GMP standards, the company has implemented a comprehensive quality management system. This ensures strict quality control throughout the entire process—from raw material sourcing and production to testing and final product release—guaranteeing a reliable supply chain and meeting the demands of global customers. Meska Joinway is equipped with advanced analytical instruments, including Agilent gas chromatographs and PE atomic absorption spectrometers, providing essential data support for R&D and quality assurance, and consistently ensuring product excellence.



Innovation & Quality

As a national high-tech enterprise and a Zhejiang Provincial “Specialized, Refined, Unique and Innovative” SME, Meska Joinway prioritizes R&D and technical collaboration. We have built industry-academia partnerships with leading Chinese universities and maintain ISO9001, ISO45001, and ISO14001 certifications. With 10 invention patents and 12 utility model patents, we are actively pursuing international certifications including EU CEP and US FDA to support global market expansion.

TECHNICAL ADVANTAGE

Meska Joinway Pharmaceutical Co., Ltd., specializes in the development and production of high-quality pharmaceutical-grade and industrial-grade cellulose ethers. Meska Joinway's pharmaceutical-grade cellulose product line holds a leading position in China in terms of technological advancement. These products are widely used in a range of applications—including plant-based hollow capsules, film coating powders, film-forming agents, matrix materials for sustained and controlled-release formulations, binders for solid dosages, stabilizers for ointments and emulsifiable concentrates, and thickeners for lotions and gels.



New Intelligent Factory

In June 2022, Meska Joinway broke ground on a new intelligent facility in the New Material Industrial Park in Linghu Town, Huzhou. Trial production began in April 2024, with full commercial operation scheduled for January 2025.

With a total investment of RMB 1.34 billion, the plant features world-leading gas-phase production technology and China's most automated liquid-phase lines. Fully automated and integrated from production to logistics, the factory embodies a modern, green, and intelligent operational model, setting new standards in safety, efficiency, and environmental sustainability.

MESKACEL™ Hypromellose

HYDROXYPROPYL METHYLCELLULOSE

Overview

Hypromellose is a widely used pharmaceutical excipient, valued for its versatility in tablet formulation and coating. It serves as an effective film-coating material and a reliable binder during granulation, and is available in a range of viscosity grades to meet diverse application needs.

Meskacel™ Hypromellose offers excellent film-forming properties, delivering a smooth and elegant finish to coated tablets. Its versatility makes it suitable for a variety of film-coated dosage forms. As a binder, Meskacel™ exhibits superior stability and non-ionic characteristics, ensuring broad compatibility without interacting with active ingredients.

Specification

Item	Grade		
	ME(2910)	MF(2906)	MK(2208)
Methoxy(WT%)	28.0-30.0	27.0-30.0	19.9-24.0
Hydroxypropoxy(WT%)	7.0-12.0	4.0-7.5	4.0-12.0
Gelation temperature(°C)	58.0-64.0	62.0-68.0	70.0-90.0
Viscosity(mPa.s) (2% solution,20°C)	4, 5, 6, 15, 50, 4000	50, 4000	100, 4000, 15000, 100000
Lossing on drying(%)	≤5.0		
Residue on ignition(WT%)	≤1.5		
pH	4.0-8.0		

Available Grades and Recommended Applications

Grade	Reference dosage	Advantages	Application
ME3,4,5,6,15	0.5-5%	Recommended to use as coatings of organic solvent containing water. The features of robust film forming and high viscosity enable the coating to form a barrier to increase its compressive strength, and reduce fragment as well.	Film Coating
ME3,4,5,6,15	1-5%	Mixed with Ethyl Cellulose, it can be used as a coating of organic solvent in bid to form a solid and adhesive film which masks the bitter taste of tablet.	Film Coating
ME5,6,15	3-20%	It can be adopted as controlled release coating that adjusts the diffusion while mixed with Ethyl Cellulose.	Controlled release
ME15 ME50	2-6%	With the features like low density, high hardness, low friability and outstanding disintegration properties, it can be added for tablet production while the pressure of the machine is low during the process which renders equipment lifespan extended.	Granulation, Tablet Binder
ME15 ME4000	1-2%	For the solid particles, it plays a good role in floating and anti-microbe.	Antacid
ME50 ME4000	0.1-0.5%	It has good performance of lubrication and thickening for the solvent of high clarity and low concentrations.	Eyedrop
ME4000	1-2%	It can be used for the effect of solid suspension.	Suspending
ME4000 MK4000	1-5%	Being taken the advantages of protective effects of colloid and emulsifying properties, it is conducive to forming liquid drugs.	Emulsions, gels, ointments
ME4000 MK4000	5-30%		Aperient
MK100 MK4000 MK15000 MK100000	5-75%	It is recommended for the application of sustained release matrix tablets with the MK powder grade having the fastest rate of hydration.	Controlled release

MESKACEL™ L-HPC

LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE(L-HPC)

Overview

Meskacel™ L-HPC is a low-substituted ether of cellulose. It is non-ionic, less reactive to active ingredients, insoluble in water and alcohol but swells in water by holding water molecules around hydroxypropyl groups that are distributed on the cellulose backbone. L-HPC is widely used as a dual-functionality excipient (binder-disintegrant) for tablets, granules or other pharmaceutical solid dosage forms depending on its particle size and substituent content. Tablets containing L-HPC disintegrate into very fine individual particles thus resulting in rapid drug dissolution.

Meskacel™ is used as a binder and a disintegrant for solid medicaments. The unique character of this product exhibits a wide range of compatibility with many active substances. This is a suitable binder and disintegrant for a formulation study. We offer these products under the brand of Meskacel LP Series. Currently three grades are commercially available from Meska Joinway. They have different particle sizes or shapes and chemical substitution levels.

Specification

Item	Grade		
	LP11	LP21	LP22
Hydroxypropoxy(WT%)	100-129	100-129	70-99
Lossing on drying(%)	≤5.0	≤5.0	≤5.0
Chlorides(WT%)	≤0.36	≤0.36	≤0.36
Residue on Ignition(WT%)	≤0.5	≤0.5	≤0.5
Particle size(um)	50	40	40
Particle type	Highly fibrous	Moderately fibrous	Moderately fibrous
Method of Application	Direct compression (anti-capping)	Regular grade (dry-mixing,wet granulation)	Lower hydroxypropyl (sometimes has better disintegration)

Recommended Applications

Tablet Anti-capping

One of the benefits of L-HPC is to resolve "capping", which is a typical problem in the tableting process. Several reports have pointed out that capping is caused by a high residual die-wall pressure during the tableting process, L-HPC reduces the residual die-wall force and ejection force during the tableting process. LP-11, the highly fibrous grade, is the most effective for anti-capping, as entangling of fibers is important for capping prevention.

Tablet Dry binder(direct compression)

Low-Substituted Hydroxypropyl Cellulose(L-HPC) has been used as disintegrant for solid dosage forms for many years. This polymer is not water-soluble, but it swells by holding water molecules around hydroxypropyl groups that are distributed on the cellulose backbone.

Tablet Quick disintegration

Active ingredients with poor solubility and low wettability, you can use a higher amount of L-HPC to improve disintegration. Even as much as 20-40% of L-HPC has been disintegrated in very fine individual particles, so the dissolution is rapid and complete.

Dispersing aid (for capsule filing)

The release of a drug is filled in hard capsules tends to be delayed because the materials in the capsules are clogged, this delay is especially significant for herbal medications. However, if L-HPC is used together with a drug as a filler, clogging can be prevented because L-HPC absorbs water and disintegrates in a shorter time, which results in the rapid release of the drug.



COMPANY HISTORY

With a global presence spanning multiple countries, we have cultivated trusted, long-term partnerships with pharmaceutical companies worldwide. Our experienced team is committed to providing innovative, regulatory-compliant solutions that address complex challenges in product processing, performance enhancement, and drug delivery systems—all while upholding the stringent standards of a highly regulated industry.



Meska Joinway is advancing with a new spirit of exploration, innovation, and action.

2003	2004	2010	2016	2022	2024	2025
● Founding	● Start	● Meska	● Stock	● Expansion	● New Step	● New Start

It's an era of dreams and passions. In 2003, Zhejiang Joinway Pharmaceutical Co., Ltd. was established.

In 2004, the company obtained the Drug Manufacturing License.

In 2010, Meska Group acquired Zhejiang Joinway Pharmaceutical Co., Ltd.

In 2016, the company was successfully listed on the NEEQ (Stock Code: 838717.OC)

In 2022, the groundbreaking ceremony for the new plant with an annual production capacity of 38,000 tons was held. Branch company Zhejiang Meska New Material established targeting for global businesses.

In 2024, the construction of the new plant with an annual production capacity of 38,000 ton was completed.

In 2025, the new plant was officially put into operation. Meska Joinway Pharmaceutical Co., Ltd. has a new start with a bigger dream.

